Tag: malignant kidney neoplasm

FDA Approves Cabozantinib for Differentiated Thyroid Cancer

The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of locally advanced or metastatic differentiated thyroid cancer (DTC) in adults...

‘Dawn of a New Era’ in the Treatment of Renal Cell Carcinoma

The decades-long search for a safe, effective adjuvant therapy for patients with resected kidney cancer at high risk of recurrence appears to have taken a...

FDA OKs Belzutifan for Cancers Tied to von Hippel-Lindau Disease

The US Food and Drug Administration (FDA) approved belzutifan (Welireg) for adult patients with von Hippel-Lindau disease (VHL) who require therapy for associated renal cell...

Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU

Combination therapy with the immunotherapies nivolumab (Opdivo) and ipilimumab (Yervoy) is now approved in the European Union for the first-line treatment of adults with unresectable...

Which Patients With Kidney Cancer Are Likely to Respond to ICI?

Several factors associated with a diminished response to immune checkpoint inhibitor (ICI) drugs among patients with metastatic clear cell renal cell carcinoma (ccRCC) have been...

Obesity ‘Clearly’ Not Tied to Worse Survival in MBC

The relationship between obesity and overweight and breast cancer has some elements of mystery. But this is not one of them: in metastatic breast cancer...

Real-World Results With Checkpoint Inhibitors Inferior to CT Data

Real-world survival outcomes for cancer patients on immune checkpoint inhibitors (ICIs) are inferior to outcomes reported in patients on clinical trials of ICIs, according to research...

Predicting Complications of Cytoreductive Nephrectomy in mRCC

Patients with higher intraoperative blood loss and those treated at lower-volume surgical centers had a greater risk of high-grade complications after undergoing cytoreductive nephrectomy (CN)...

Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks

Promoting to the front line two drugs normally used in rearguard action to treat advanced renal cell carcinoma (RCC) ― nivolumab (Opdivo) and cabozantinib (Cabometyx)...

‘Every Patient Would Applaud’ Bladder Cancer Surveillance Study

A new, less intensive approach to follow-up of patients with high-risk, non-muscle invasive bladder cancer (NMIBC) after surgery appears feasible. Usually, such patients follow an...